Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Total Liabilities (2017 - 2025)

Inmune Bio's Total Liabilities history spans 9 years, with the latest figure at $8.0 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 43.43% year-over-year to $8.0 million; the TTM value through Sep 2025 reached $8.0 million, down 43.43%, while the annual FY2024 figure was $7.5 million, 60.42% down from the prior year.
  • Total Liabilities for Q3 2025 was $8.0 million at Inmune Bio, down from $8.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $21.7 million in Q4 2022 and bottomed at $2.3 million in Q1 2021.
  • The 5-year median for Total Liabilities is $17.9 million (2022), against an average of $15.3 million.
  • The largest annual shift saw Total Liabilities skyrocketed 1181.82% in 2021 before it tumbled 60.42% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $19.7 million in 2021, then grew by 9.99% to $21.7 million in 2022, then dropped by 13.04% to $18.9 million in 2023, then crashed by 60.42% to $7.5 million in 2024, then increased by 6.9% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Total Liabilities are $8.0 million (Q3 2025), $8.8 million (Q2 2025), and $8.1 million (Q1 2025).